Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd Share Price Today: Live Updates & Key Insights

Get insights on Syncom Formulations (India) Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Syncom Formulations (India) Ltd Share Price Chart

Syncom Formulations (India) Ltd Fundamentals

Traded Volume: 11,66,382

Market Cap(Cr): 1,511

Avg Traded Price 13.81

1 Year return -24.41%

Upper Circuit 16.3

Lower Circuit 15.9

P/E TTM 26.00

P/B Ratio 1.00

Traded Value(Cr) 187.44

EPS TTM 0.612

Book value 0.612

Dividend 0.00%

Syncom Formulations (India) Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Syncom Formulations (India) Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Syncom Formulations (India) Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -3.54%

1M -2.25%

3M -10.42%

1Y -24.41%

YTD -22.72%

Syncom Formulations (India) Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Syncom Formulations (India) Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 13.44L

Day Before Yesterday 11.25L

1W Avg 12.50L

1M Avg 11.06L

3M Avg 9.33L

Syncom Formulations (India) Ltd Technical Details

Syncom Formulations (India) Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 16

Support 2 16

Support 3 16

Pivot Point : 16

Resistance 1 16

Resistance 2 16

Resistance 3 17

Syncom Formulations (India) Ltd Corporate Actions

Syncom Formulations (India) Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Syncom Formulations (India) Ltd’s capital allocation strategies.

All

Ex-Date 09-Sep-2022 Type D Description 0.03/share@3.00% Record Date 07-Nov-2025 Ratio 3.00

Ex-Date 21-Sep-2017 Type D Description 0.02/share@2.00% Record Date 07-Nov-2025 Ratio 2.00

Ex-Date 22-Sep-2016 Type D Description 0.02/share@2.00% Record Date 07-Nov-2025 Ratio 2.00

Ex-Date 16-Sep-2015 Type D Description 0.02/share@2.00% Record Date 07-Nov-2025 Ratio 2.00

Ex-Date 18-Sep-2014 Type D Description 0.02/share@2.00% Record Date 07-Nov-2025 Ratio 2.00

Ex-Date 19-Aug-2013 Type B Description share@5:2 Record Date 20-Aug-2013 Ratio 5:2

Ex-Date 19-Aug-2013 Type S Description share@1:10.00 Record Date 20-Aug-2013 Ratio 1:10.00

Ex-Date 10-Jul-2013 Type D Description 0.60/share@6.00% Record Date 07-Nov-2025 Ratio 6.00

Ex-Date 20-Sep-2012 Type D Description 0.60/share@6.00% Record Date 07-Nov-2025 Ratio 6.00

Ex-Date 22-Sep-2011 Type D Description 0.50/share@5.00% Record Date 07-Nov-2025 Ratio 5.00

Ex-Date 23-Sep-2010 Type D Description 0.50/share@5.00% Record Date 07-Nov-2025 Ratio 5.00

Ex-Date 24-Sep-2009 Type D Description 0.50/share@5.00% Record Date 07-Nov-2025 Ratio 5.00

Ex-Date 13-May-2009 Type R Description /share@1:2% Record Date 20-May-2009 Ratio 1:2

Ex-Date 23-Sep-2008 Type D Description 0.50/share@5.00% Record Date 07-Nov-2025 Ratio 5.00

Ex-Date 20-Sep-2007 Type D Description 1.00/share@10.00% Record Date 07-Nov-2025 Ratio 10.00

Dividends

Announcement Date 09-Sep-2022 Ex Dividend Date 09-Sep-2022 Dividend(%) 3

Announcement Date 21-Sep-2017 Ex Dividend Date 21-Sep-2017 Dividend(%) 2

Announcement Date 22-Sep-2016 Ex Dividend Date 22-Sep-2016 Dividend(%) 2

Announcement Date 16-Sep-2015 Ex Dividend Date 16-Sep-2015 Dividend(%) 2

Announcement Date 18-Sep-2014 Ex Dividend Date 18-Sep-2014 Dividend(%) 2

Announcement Date 10-Jul-2013 Ex Dividend Date 10-Jul-2013 Dividend(%) 6

Announcement Date 20-Sep-2012 Ex Dividend Date 20-Sep-2012 Dividend(%) 6

Announcement Date 22-Sep-2011 Ex Dividend Date 22-Sep-2011 Dividend(%) 5

Announcement Date 23-Sep-2010 Ex Dividend Date 23-Sep-2010 Dividend(%) 5

Announcement Date 24-Sep-2009 Ex Dividend Date 24-Sep-2009 Dividend(%) 5

Announcement Date 23-Sep-2008 Ex Dividend Date 23-Sep-2008 Dividend(%) 5

Announcement Date 20-Sep-2007 Ex Dividend Date 20-Sep-2007 Dividend(%) 10

Bonus

Record Date 20-Aug-2013 Ex-Bonus Date 19-Aug-2013 Ratio 5:2

Splits

Record Date 20-Aug-2013 Split Date 19-Aug-2013 Face Value (Before/After) 10.00/1.00

Others

Ex-Rights Date 13-May-2009 Premium(Rs.) 7.00 Ratio 1:2

Syncom Formulations (India) Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Syncom Formulations (India) Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Syncom Formulations (India) Ltd's relative performance and valuation against major competitors.

Stock Name Windlas Biotech Ltd ₹869.85 (-5.74%) M. Cap (Cr) 18.33 1 Yr Return (%) -22.92% P/E (TTM) 27.08 PB Ratio 3.87

Stock Name Shukra Pharmaceuticals Ltd ₹40.97 (+1.99%) M. Cap (Cr) 17.94 1 Yr Return (%) +491.20% P/E (TTM) 177.28 PB Ratio 33.05

Stock Name Beta Drugs Ltd ₹1670.20 (-4.01%) M. Cap (Cr) 16.86 1 Yr Return (%) -11.63% P/E (TTM) 39.75 PB Ratio 9.32

Stock Name Syncom Formulations (India) Ltd ₹16.07 (-0.12%) M. Cap (Cr) 15.11 1 Yr Return (%) -24.41% P/E (TTM) 26.24 PB Ratio 4.41

Stock Name Jagsonpal Pharmaceuticals Ltd ₹216.04 (-0.29%) M. Cap (Cr) 14.42 1 Yr Return (%) -11.28% P/E (TTM) 23.27 PB Ratio 7.31

Stock Name Bajaj Healthcare Ltd ₹442.80 (-0.82%) M. Cap (Cr) 13.99 1 Yr Return (%) +15.27% P/E (TTM) 30.51 PB Ratio 3.14

Stock Name Sigachi Industries Ltd ₹35.77 (+0.08%) M. Cap (Cr) 13.67 1 Yr Return (%) -31.17% P/E (TTM) -24.83 PB Ratio 2.27

Syncom Formulations (India) Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Syncom Formulations (India) Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 23.31 Mar 2024 -5.94 Mar 2023 10.50 Mar 2022 16.33 Mar 2021 -150.15

PARTICULARS Investing Activities Mar 2025 -18.38 Mar 2024 83.83 Mar 2023 -44.97 Mar 2022 -27.07 Mar 2021 75.46

PARTICULARS Financing Activities Mar 2025 -67.59 Mar 2024 -15.37 Mar 2023 35.00 Mar 2022 8.29 Mar 2021 71.96

PARTICULARS Net Cash Flow Mar 2025 -62.66 Mar 2024 62.52 Mar 2023 0.53 Mar 2022 -2.45 Mar 2021 -2.73

Syncom Formulations (India) Ltd Shareholding Pattern

This shows the ownership breakdown of Syncom Formulations (India) Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 50.57%

Public 49.33%

Other Institutions 0.0%

FII 0.1%

Mutual Funds null%

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda.In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis.In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995.During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%.During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.The modernisation of injectable section by putting Tunnel System and other modern equipments and expansion of tablet department byputting high speed mega press machines was completed in 2002. The Company carried out an expansion program of the installedcapacities of its manufacturing unit at Pithampur, Dist. Dhar to increase the capacity of tablet section by 35% and also doubling of thecapacity of capsule section. Capacity of packing section was increased in line with the increase in capacity of the said formulationsections. The expansion cum modernization program was implemented at a total cost of Rs. 1.34 crore out of which the major expenditure was incurred in 2002-03. The expanded capacities were made available for production from May, 2003.In 2007, the Company launched a new division Cratus Life Care to expand its operations. The expansion cum modernization project at Pithampur unit was completed with the total investment costing Rs 15.17 Crore during the year 2007-08. The Company raised long term financial resources by way of preference issuance of 3,10,000 equity shares of Rs.10 each at a premium of Rs.36 per share on 29 March, 2008 to the promoters of the Company and the said Equity got listed with the BSE in 2008.In 2023-24, Company has expanded the business by increasing the overall production capacity of Injectable capacity from 200 Lakhs to 300 Lakhs per annum.

Chairman & Exec. Director

Kedarmal Bankda

Registered office 7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd, Mumbai, Maharashtra, 400093

FAX :91-22-30887744

Background

Incorporation Year 1988

Face Value ₹1.00

Market Lot 1

Syncom Formulations (India) Ltd Latest News

VIEW MORE NEWS

FAQs on Syncom Formulations (India) Ltd